Abstract
Anticancer drug research and development is a high-risk endeavor. Among investigational drugs with oncology as the lead indications that entered phase 1 trials between 2003 and 2011 (n = 489), only one in eight (13.2%) of phase 1 anticancer drugs were eventually approved (Hay et al., 2014). The recent decade has witnessed a shift of focus in anticancer drug development from cytotoxic drugs to molecular targeted agents (MTAs) and immuno-oncology therapies. Responding to this shift, the development paradigm and regulatory process for investigational anticancer drugs also underwent significant changes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
